| | Oral (N = 22) | Intravenous (N = 65) | p value |
|---|
Whole adverse events | 8 (36%) | 20 (31%) | 0.79 |
Tremor | 4 (18%) | 8 (12%) | 0.49 |
Nausea | 1 (5%) | 3 (5%) | 1 |
Hot flush | 1 (5%) | 2 (3%) | 1 |
Kidney disorder | 2 (9%) | 2 (3%) | 0.26 |
Peripheral neuropathy | 1 (5%) | 2 (3%) | 1 |
Headache | | 1 (2%) | |
Tachycardia | | 1 (2%) | |
Rash | | 1 (2%) | |
Hematopenia | | 1 (2%) | |
Pneumonia | | 1 (2%) | |
- Less than one-third of patients experienced adverse events in both tacrolimus groups during the study. Most adverse events were non-serious, including tremors, nausea, hot flashes, and peripheral neuropathies, and did not require tacrolimus discontinuation or additional treatment. Kidney disorder was a common adverse event; four patients had slight kidney disorders that recovered with dose reduction of tacrolimus and did not require tacrolimus discontinuation. One patient had pneumonia which required discontinuation of tacrolimus and colectomy
- Categorical variables were compared using Fischer’s exact test
